R. Kate (Katie) Kelley, MD

Harvard College, Boston, MA, B.A., 1993-97, Biochemistry
UCLA, M.D., 1998-2002, Medicine
UCLA, Intern, 2002-05, Medicine
UCLA, Resident, 2005-06, Medicine
UCSF, Fellow, 2006-09, Hematology/Oncology

• 2005-2006
  University of California, Los Angeles, Clinical Instructor, Medicine
• 2010-present
  University of California, San Francisco, Health Sciences Assistant Clinical Professor of Medicine: Step 1
• 2010-present
  San Francisco Veteran's Administration Medical Center, Staff Physician

• 1993-1997
  Harvard College Scholarship, Harvard College
• 1993-1997
  Elizabeth Cary Agassiz Merit Award, Harvard College
• 1997-1998
  Rotary Ambassadorial Scholarship, Costa Rica
• 2001
  Alpha Omega Alpha, UCLA School of Medicine
• 2001
  Merck Book Award, UCLA School of Medicine
• 2001
  Janet M. Glascow Memorial Achievement Citation, American Medical Women's Association
• 2004, 2006
  Solomon Scholars Resident Research Day Award, UCLA Department of Medicine
• 2006
  Medical Student Teaching Award, UCLA Department of Medicine
• 2009
  ASCO Cancer Foundation Merit Award, Gastrointestinal Cancers Symposium
• 2010
  ASCO Young Investigator Award

• Riggs J, Litchfield R*, Smith B. Molecular recognition and membrane transport with mixed-ligand borates. Journal of Organic Chemistry 61(3), 1996: 1148-50. (*Maiden name)
• Kelley R and Ko A. Erlotinib in the treatment of advanced pancreatic cancer. Biologics: Targets and Therapy 2(1), 2008: 1-13.
• Kelley RK and Venook AP. Mutated ras as a predictor of response: is it ready for the clinic? CMPMedica LLC, May 2008.
• Kelley RK and Venook AP. KRAS developments and implementation of the findings. HemOnc Today 9(16), 2008: 2.
• Kelley RK and Venook AP. Sorafenib in hepatocellular carcinoma. Journal of Clinical Oncology 26(36), 2008: 5845-48.
• Kelley RK and Venook AP. Drug development in advanced colorectal cancer: Challenges and opportunities. Current Oncology Reports 11(3), 2009: 175-85.
• Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemotherapy Pharmacology, published online 4 February 2010.
• Kelley RK and Venook AP. Prognostic and predictive markers in stage II colon cancer: Is there a role for gene expression profiling? Accepted for publication in Clinical Colorectal Cancer, May 2010.
• Kelley RK and Venook AP. Non-Adherence to Imatinib Therapy During an Economic Downturn. Accepted for publication in New England Journal of Medicine, May 2010.